Phathom Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Frazier Life Sciences Public Fund increases its stake in Phathom Pharmaceuticals following a merger with Frazier Life Sciences Public Overage Fund.
NASDAQ
Frazier Life Sciences and affiliated entities filed an amended Schedule 13D, clarifying their beneficial ownership in Phathom Pharmaceuticals, Inc. and correcting prior attributions.
NASDAQ
SCHEDULE 13D/A: Frazier Life Sciences Funds Increase Stake in Phathom Pharmaceuticals, Reaching Nearly 20% Beneficial Ownership
Frazier Life Sciences and its affiliated funds have significantly increased their beneficial ownership in Phathom Pharmaceuticals, Inc., now holding an aggregate of approximately 19.9% of the common stock.